Pfizer Inc. (NYSE:PFE) Shares Purchased by Philip James Wealth Mangement LLC

Philip James Wealth Mangement LLC raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 3.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 331,466 shares of the biopharmaceutical company's stock after acquiring an additional 11,035 shares during the quarter. Pfizer accounts for about 1.0% of Philip James Wealth Mangement LLC's holdings, making the stock its 18th biggest position. Philip James Wealth Mangement LLC's holdings in Pfizer were worth $8,399,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Rialto Wealth Management LLC acquired a new position in Pfizer during the fourth quarter worth about $26,000. Clarity Asset Management Inc. purchased a new position in shares of Pfizer during the 4th quarter worth approximately $27,000. Gould Capital LLC raised its position in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer in the 4th quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Pfizer during the 4th quarter valued at $30,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Cantor Fitzgerald started coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. UBS Group upped their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Finally, Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Price Performance

Shares of PFE stock opened at $24.30 on Friday. The firm has a fifty day simple moving average of $23.42 and a 200-day simple moving average of $24.85. The company has a market capitalization of $138.18 billion, a PE ratio of 17.61, a price-to-earnings-growth ratio of 0.88 and a beta of 0.57. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period last year, the firm earned $0.82 earnings per share. The company's revenue was down 7.8% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.08%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.